Serum IL-17A and CCL20 levels and their correlation with obsessive-compulsive disorder and suicidality in schizophrenia and bipolar mood disorder Authors: Zanireh Salimi, Mojtaba Norouzi, Mostafa Eghbalian, Yasser Bagheri, Najmeh Shahini, Parisa Ghasemi Noghabi Published: 2026 ABSTRACT AbstractBackgroundIL-17A and CCL20 are key inflammatory mediators involved in neuroinflammation linked to schizophrenia (SCZ) and bipolar mood disorder (BMD), influencing disease severity and representing potential biomarkers and therapeutic targets. This study aimed to assess serum IL-17A and CCL20 levels in SCZ and BMD patients and explore their associations with obsessive-compulsive disorder (OCD) symptoms and suicidality.MethodsA cross-sectional study was conducted in 2024 at Ibn Sina Psychiatric Hospital, Mashhad, Iran, involving inpatients diagnosed with SCZ or BMD during acute episodes. Consecutive sampling was used to enroll eligible patients aged 18 to 65 who met the inclusion criteria, excluding those with substance use disorders, autoimmune diseases, recent infections, or on immunosuppressive therapy. Demographic and clinical data, including OCD and suicidality status, were collected via interviews and medical records. Serum IL-17A and CCL20 levels were measured using ELISA kits after overnight fasting. Statistical analyses included t-tests, Mann-Whitney U, chi-square, logistic regression, and generalized linear model tree (GLMtree) models, considering a p-value of less than 0.05 as statistically significant.ResultsThe study included patients with a mean age of 39.81 ± 10.36 years. BMD patients showed greater employment rates and more suicidal thoughts (p < 0.001). Serum IL-17A and CCL20 levels did not differ significantly between SCZ and BMD groups. Logistic regression revealed a probability inverse association between IL-17A and suicidal thoughts in BMD patients (β = -0.406). GLMtree analysis demonstrated that increased IL-17A was probably associate with greater OCD severity in females and a complex interaction with electroconvulsive therapy (ECT) history, while seemingly IL-17A’s association with suicidal thoughts differed by diagnosis, ethnicity, and medication use (p < 0.05).ConclusionThe study found that suicidal thoughts and suicide cases were more common in BMD patients. Although serum IL-17A and CCL20 levels did not differ between SCZ and BMD groups, lower IL-17A were associated with greater suicidality in BMD. The relationship between IL-17A, OCD, and suicidal ideation was maybe influenced by gender, ethnicity, treatment, and diagnosis, underscoring the complex immune-psychiatric interactions in these disorders.Keywords: Schizophrenia, Bipolar mood disorder, IL-17A, CCL20 Introduction Schizophrenia (SCZ) and bipolar mood disorder (BMD) are among the most severe and disabling psychiatric conditions worldwide, significantly impacting patients’ quality of life, functionality, and overall health. These disorders contribute substantially to the global burden of mental illness due to their chronic nature, early onset, and high rates of comorbidity and mortality [1, 2]. Regarding prevalence, SCZ affects about 24 million people globally, corresponding to approximately 1 in 300 individuals [3]. BMD has an estimated global prevalence of 1 in 200, with around 37 million people affected worldwide [4]. In Iran, epidemiological data indicate that psychiatric disorders affect a sizable proportion of the population, with a national survey reporting a 23.6% prevalence of any psychiatric disorder, and 63.8% of them suffered from moderate to severe illness [5]. Emerging evidence highlights the critical involvement of the immune system and chronic inflammation in the pathophysiology of SCZ and BMD. SCZ is associated with abnormalities across nearly all components of the immune system, from innate to adaptive immunity, alongside elevated levels of inflammatory markers such as cytokines and chemokines. These peripheral immune abnormalities contribute to neuroinflammation, which is linked to cognitive deficits and neuroanatomical alterations in patients with SCZ [6, 7]. Similarly, BMD demonstrates increased peripheral inflammation during both depressive and manic phases, with elevated proinflammatory cytokines playing a role in exacerbating mood symptoms and contributing to comorbid metabolic disturbances [8, 9]. Chronic inflammation is proposed to interact bidirectionally with neuropsychiatric symptoms, potentially driving disease progression and influencing clinical outcomes [10]. This neuroimmune dysregulation underscores a growing recognition that inflammatory pathways may serve as key targets for understanding and treating these complex psychiatric conditions. IL-17 A and CCL20 play significant roles in the inflammatory processes underlying psychiatric disorders. IL-17 A is a proinflammatory cytokine predominantly produced by Th17 cells, which has been implicated in neuroinflammation contributing to the pathogenesis of major psychotic disorders, including SCZ and BMD. Elevated serum levels of IL-17 A have been observed in patients with these conditions, suggesting its involvement in disease mechanisms and potential as a therapeutic target [11]. CCL20, a chemokine that binds to the CCR6 receptor, is also elevated in SCZ and is involved in recruiting immune cells to inflamed tissues, thereby facilitating the effects of the IL-17 pathway. Studies indicate that CCL20 expression correlates with disease activity and may modulate immune responses linked to neuropsychiatric symptoms [12, 13]. The IL-17 A-CCL20 axis thus represents a crucial inflammatory pathway that may influence symptom severity, progression, and potentially suicidality in psychiatric disorders, highlighting its significance for biomarker development and targeted interventions. Despite growing evidence of elevated serum IL-17 A and CCL20 levels in major psychotic disorders such as SCZ and BMD, there remains a significant gap in understanding how these immune markers relate to specific clinical features like obsessive-compulsive disorder (OCD) spectrum symptoms and suicidality [11]. Moreover, the contribution of these inflammatory mediators to neuropsychiatric manifestations such as OCD symptoms and suicidal behaviors, which represent common and clinically challenging comorbidities, is not well elucidated. Exploring these relationships is crucial because it may shed light on underlying pathophysiological mechanisms that connect immune dysregulation with distinct symptom clusters. Understanding these links could facilitate the development of novel biomarkers for predicting clinical outcomes and tailoring personalized interventions targeting immunological pathways. To enhance the modeling of complex relationships in our dataset, we moved beyond Logistic regression models, which assumes linearity and often fails to capture nonlinear patterns or interactions [14, 15], and employed advanced tree-based approaches. In addition, we applied the generalized linear model tree (GLMtree) method, a powerful hybrid that combines the partitioning strength of decision trees with generalized linear models fitted at the terminal nodes [16]. Together, these models allowed a more detailed, flexible, and nuanced examination of the predictors, accommodating both linear and nonlinear associations as well as heterogeneous effects across subgroups [17]. Therefore, this study aimed to measure the serum levels of IL-17A and CCL20 in patients diagnosed with SCZ and BMD. Additionally, the study sought to evaluate the association of these inflammatory markers with OCD symptoms and suicidality within these patient groups by using GLMtree. Methods Study design and sampling In 2024, a cross-sectional study was carried out at Ibn Sina Psychiatric Hospital in Mashhad, Iran. The study population consisted of inpatients diagnosed with SCZ or BMD. A consecutive sampling method was employed, whereby all eligible patients admitted with acute episodes of SCZ or BMD during the study period were invited to participate. Patients who fulfilled the inclusion criteria and consented to participate were consecutively enrolled until the planned sample size was achieved. Eligibility criteria The study included patients between 18 and 65 years old with a confirmed diagnosis of SCZ or BMD who were admitted for an acute psychiatric episode. Individuals were excluded if they had substance use disorders, autoimmune conditions, recent infections, or were receiving immunosuppressive therapy. Data collection Demographic and clinical data were collected through patient interviews and medical records. Data collected included age, sex, ethnicity, education level, occupation, smoking status, history of hospitalization frequency, illness duration, suicide and OCD status, and medication usage (categorized as multiple drug groups, second-generation antipsychotics/first-generation antipsychotics [SGA/FGA], or no medication). Cytokine measurement Serum levels of IL-17A and CCL20 were measured using enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis, MN, USA; IL-17A: Catalog #D1700, sensitivity of 15 pg/mL, intra-assay coefficient of variation (CV) below 5%; CCL20: Catalog #DM3A00, sensitivity of 10 pg/mL, intra-assay CV below 6%). Blood samples were obtained after an overnight fast, centrifuged at 3000 rpm for 10 min, and then stored at − 80 °C until further analysis. Clinical assessments Clinical assessments included the PANSS for psychosis severity, Hamilton Depression Rating Scale (HDRS) for depressive symptoms in BMD, and Young Mania Rating Scale (YMRS) for manic symptoms in BMD. Suicidal ideation was assessed via clinical interviews and HDRS item 3. All patients diagnosed with bipolar mood disorder were admitted during an acute manic episode. Clinical phase was confirmed by psychiatrist based on DSM-5 criteria at the time of hospitalization. No patients in depressive, mixed, or euthymic states were included in the bipolar group. Diagnostic criteria for SCZ, BMD, OCD, and suicidality Diagnoses of SCZ and BMD were established by board-certified psychiatrists according to the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). All diagnoses were confirmed through structured clinical interviews. OCD were evaluated as obsessive-compulsive symptoms occurring within the acute phase of SCZ or BMD, rather than as a separate comorbid psychiatric disorder. OCD were assessed by a board-certified psychiatrist during admission through a semi-structured clinical interview based on DSM-5 criteria, with symptom presence or absence documented in the clinical notes and confirmed through the admission evaluation. Suicidality was defined as the presence of recent suicidal ideation and/or a suicide attempt. Suicidal behavior and ideation were systematically evaluated at admission by the treating psychiatrist using a structured suicidality checklist alongside a clinical interview. Patients were categorized into one of three groups: (1) no current suicidality, (2) current suicidal ideation without a recent attempt, and (3) suicide attempt within the past months. All assessments were conducted during the acute admission period, prior to blood sampling, to ensure maximal correspondence between clinical status and biomarker measurements. Sample size The sample size for this study was determined to provide adequate statistical power to detect significant differences between SCZ and BMD groups. The calculation utilized standard sample size formulas for comparing means or proportions between two groups, with a significance threshold (α) set at 0.05 and a power of 80%. Ultimately, the study included a total of 140 patients (71 with SCZ and 69 with BMD). Statistical analyses Descriptive statistics summarized demographic and clinical characteristics. Continuous variables were compared between SCZ and BMD groups using independent t-tests or Mann–Whitney U tests when assumptions were violated. Categorical variables were analyzed using chi-square tests. Logistic regression models assessed associations between IL-17A and CCL20 levels and clinical outcomes, including OCD, suicidal thoughts, and suicide occurrence within each diagnosis group. To control for potential confounding effects of medication, we accounted for drug usage in our analyses. Participants’ medication status was categorized into multiple groups: SGA, FGA, or no medication. GLMtree analyses were performed to evaluate interactions between cytokine levels and demographic variables affecting OCD, suicidal thoughts, and suicide risk, adjusting for confounders. Only statistically significant models from GLMtree analyses were reported. A significance level of 0.05 and 95% confidence intervals were applied for all tests. Statistical analyses were conducted using R software version 4.5.0, employing the packages “ggbarstats,” “ggbetweenstats,” and “glmtree.” Ethical statement This study was approved by the Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.REC.1402.033) in accordance with the Declaration of Helsinki. All participants or their legal guardians provided written informed consent prior to enrollment. For patients experiencing acute episodes, consent was obtained once they were clinically stable enough to understand and voluntarily sign the consent form, as approved by the institutional ethics committee. Results Table 1 shows a description of demographic factors of SCZ and BMD patients. The mean age of the patients was 39.81 ± 10.36 years. SCZ patients were hospitalized 7.68 times, which was more than BMD patients who were hospitalized 5.59 times (p-value = 0.049). Also, the average illness duration of patients was 12.05 ± 7.24 years. 60% of patients were female, a higher percentage of patients were undergraduates, and a higher percentage of BMD patients were employed than SCZs (p-value = 0.031). 76.4% of the patients were Persians, a higher percentage of Turkmen were BMD, and a higher percentage of Sistanis were SCZ (p-value = 0.008). 41.4% of patients were smokers, and 37.1% were opium users. 54.3% of patients were taking medication from more than one drug group, 25% were taking SGA/FGA drugs, and 17.1% were not taking any drug group. Table 1Description of demographic factors of Schizophrenic and Bipolar mood disorder patientsVariablesTotalSchizophrenia (n = 71)BMD (n = 69)p-value*Mean ± SDAge (year)39.81 ± 10.3641.04 ± 9.9338.55 ± 10.710.156BMI25.05 ± 4.8524.57 ± 4.7825.53 ± 4.910.243Hospitalization Number6.65 ± 6.417.68 ± 6.695.59 ± 5.970.049*Illness Duration12.05 ± 7.2412.46 ± 7.4011.62 ± 7.100.523Frequency (%)SexMale84(60.0)52(61.9)32(38.1)0.001*Female56(40.0)19(33.9)37(66.1)EducationUndergraduate80(57.1)39(48.8)41(51.2)0.692Diploma47(33.6)24(51.1)23(48.9)University13(9.3)8(61.5)5(38.5)JobNo71(50.7)42(59.2)29(40.8)0.031*Yes69(49.3)29(42.0)40(58.0)RaceFars107(76.4)58(54.2)49(45.8)0.008*Sistani11(7.9)8(72.7)3(27.3)Turkmen22(15.7)5(22.7)17(77.3)ECTNo57(40.7)30(52.6)27(47.4)0.419Yes83(59.3)41(49.4)42(50.6)Hospitalization historyNo29(20.7)13(44.8)16(55.2)0.535Yes111(79.3)58(52.3)53(47.7)CigarettesNo82(58.6)38(46.3)44(53.7)0.145Yes58(41.4)33(56.9)25(43.1)OpiumNo88(62.9)44(50.0)44(50.0)0.862Yes52(37.1)27(51.9)25(48.1)MotivationNo125(89.3)62(49.6)63(50.4)0.587Yes15(10.7)9(60.0)6(40.0)THCNo121(86.4)63(52.1)58(47.9)0.288Yes19(13.6)8(42.1)11(57.9)MedicinseNo consumption24(17.1)13(54.2)11(45.8)< 0.001*SGA/FGA35(25.0)27(77.1)8(22.9)MS5(3.6)05(100)More than 1 drug group76(54.3)31(40.8)45(59.2)* Independent T-test, p-value < 0.05BMD: bipolar mood disorder, BMI: body mass index, SD: standad deviation, ECT: electroconvulsive therapy, THC: tetrahydrocannabinol, SGA/FGA: second-generation antipsychotics/first-generation antipsychotics, MS: Mood stabilizer Description of demographic factors of Schizophrenic and Bipolar mood disorder patients * Independent T-test, p-value < 0.05 BMD: bipolar mood disorder, BMI: body mass index, SD: standad deviation, ECT: electroconvulsive therapy, THC: tetrahydrocannabinol, SGA/FGA: second-generation antipsychotics/first-generation antipsychotics, MS: Mood stabilizer Figure 1 shows status of OCD, Suicidal Thoughts, and Suicide variables, as well as the inflammatory factors IL17 and CCL20 in patients with schizophrenia and bipolar mood disorder (BMD). In the OCD variable, 8.5% of patients with schizophrenia and 10.1% of patients with BMD were affected, with no statistically significant difference between the two groups (p = 0.957). For suicidal thoughts, 8.5% of schizophrenia patients and 30.4% of BMD patients reported positive symptoms, showing a statistically significant difference (p = 0.002). Regarding suicide behavior, 15.5% of schizophrenia patients and 26.1% of BMD patients had a history of suicide, but this difference was not statistically significant (p = 0.181). The mean level of IL17 was 4.02 in the schizophrenia group and 4.22 in the BMD group, with no significant difference between groups (p = 0.478). Similarly, the median level of CCL20 was 18.31 in schizophrenia patients and 17.72 in BMD patients, also showing no statistically significant difference (p = 0.189). Status of OCD, suicidal thoughts, and suicide variables, as well as factors IL17 and CCL20 in schizophrenia and Bipolar mood disorder patients Table 2 shows the relationship between IL-17 and CCL20 in OCD, suicidal thoughts, and Suicide factors in SCZ and BMD patients by logistic regression. According to the results of logistic regression models, only the relation of IL-17 with suicidal thoughts in BMD patients was significant. Patients who had suicidal thoughts had a lower mean IL-17 than other patients (-0.406). Table 2Relationship between IL17 and CCL20 by OCD, Suicidal Thoughts, and Suicide factors in Schizophrenia and Bipolar mood disorder patientsVariablesTotalSchizophreniaBMDIL17,OCD (yes)-0.206(0.45)-0.406(0.02)-0.060(0.03)Suicidal Thoughts (yes)-0.188(0.13)0.286(0.30)-0.406(0.17) *Suicide (yes)-0.087(0.01)0.057(0.21)-0.193(0.01)CCL20,OCD (yes)0.007(0.01)0.001(0.01)0.012(0.01)Suicidal Thoughts (yes)0.001(0.01)0.012(0.01)-0.008(0.01)Suicide (yes)0.001(0.01)0.006(0.01)-0.006(0.01)* P-value < 0.05a- Logistic RegressionBMD: bipolar mood disorder, OCD:obsessive-compulsive disorder Relationship between IL17 and CCL20 by OCD, Suicidal Thoughts, and Suicide factors in Schizophrenia and Bipolar mood disorder patients * P-value < 0.05 a- Logistic Regression BMD: bipolar mood disorder, OCD:obsessive-compulsive disorder Figure 2 shows the relationship between IL17 and CCL20 in OCD, suicidal thoughts, and suicide factors by adjusting demographic variables using the GLMtree model. All models were fitted for all demographic variables, and only the results of the significant models were presented in Fig. 2. Relationship between IL17 and CCL20 by OCD, Suicidal Thoughts, and Suicide by adjusting demographic variables OCD In female patients (), with increased IL17, the severity of the tendency to have OCD was greater than in males () patients (p-value = 0.050). In patients with ECT, increased IL-17 decreased the tendency to have OCD (), while in patients without ECT, increased IL-17 increased the tendency to have OCD () (p-value = 0.008). Suicidal Thoughts In BMD patients (), the tendency to suicidal thoughts was increased when IL17 increased, while in SCZ patients (). The tendency to suicidal thoughts decreases when IL17 increases IL17 (p-value < 0.001). Also, in Fars patients (), the tendency to suicidal thoughts is increased by increasing IL17, while in Turkmen and Sistani patients (). The tendency to suicidal thoughts decreases with increasing IL17 (p-value < 0.001). In patients taking SGA/FGA drugs (), increased IL17 levels increased suicidal thoughts, while in patients in other drug groups, this severity was less () (p-value = 0.015). Discussion The study found that suicidal thoughts were significantly more frequent in BMD patients, who also accounted for the majority of suicide cases. Although serum IL-17A and CCL20 levels did not differ between groups, only IL-17A was probably associated with suicidal thoughts in BMD patients, with lower IL-17A maybe linked to increased suicidality. Further analysis revealed that IL-17A’s relationship with OCD and suicidal ideation seemingly was influenced by gender, ethnicity, treatment (ECT and antipsychotic use), and diagnosis, highlighting the complex interplay between immune factors and psychiatric symptoms in these disorders. The finding that suicidal thoughts and suicide were significantly more common in BMD patients compared to SCZ patients is consistent with the research by Dome et al. and Monson et al., who reported that BMD is consistently associated with elevated rates of suicidal ideation, attempts, and completions [18, 19]. This heightened risk is partly related to the intense mood fluctuations, impulsivity, and depressive episodes characteristic of BMD, which contribute to increased suicidal behavior [20]. Although SCZ also carries a significant suicide risk, the lifetime risk of BMD is reported to be higher in many epidemiological studies [21]. The reasons underlying this increased suicidality in BMD may include greater affective instability, higher rates of depressive and mixed episodes, and a tendency to use more lethal methods during suicide attempts [18]. Furthermore, under-recognition and inadequate long-term treatment adherence in BMD may exacerbate suicide risk [22]. Conversely, SCZ suicides tend to occur earlier in the illness course and may be influenced more by psychotic symptoms and social isolation. Pharmacological treatments have proven highly effective in reducing suicide attempts and completions among patients with BMD [23]. Additionally, comprehensive suicide prevention requires combining these treatments with psychological interventions, careful monitoring of depressive and mixed episodes, and ensuring consistent adherence to mood-stabilizing medications [24]. This study found increased serum levels of IL-17 A and CCL20 in patients with SCZ and BMD, supporting earlier research [25]. Additionally, no significant differences in serum IL-17 A and CCL20 levels were observed between SCZ and BMD patients, although IL-17 A was specifically associated with suicidal ideation in individuals with BMD. Xu et al. reported similar findings, noting changes in peripheral cytokines, including IL-17 family members, in individuals with mood disorders who exhibited suicidal ideation or behavior [26]. The inverse association observed may reflect IL-17 A’s modulation of neuroinflammatory pathways in mood-related brain regions, such as the prefrontal cortex, which are implicated in suicidality [27]. The absence of this association in SCZ may be due to differences in symptom profiles or underlying neurobiology, warranting further investigation into the role of IL-17 A in mood regulation. Potential mechanisms include the modulation of IL-17 A on neuroinflammation, blood-brain barrier integrity, and neurotransmitter systems implicated in mood regulation. Disruptions here could increase suicidal risk. Some studies propose that altered T cell function and an imbalance in Th17 cells, which produce IL-17 A, contribute to BMD pathophysiology [28]. The finding that IL-17 A’s association with OCD and suicidal ideation is influenced by gender, ethnicity, treatment modalities, and diagnosis highlights the intricate interaction between immune mechanisms and psychiatric symptoms. Gender differences in suicidal ideation and related behaviors have been well-documented in the literature. For instance, adolescent girls tend to report higher levels of suicidal ideation and attempts compared to boys, accompanied by greater depressive and anxious symptoms, rumination, and anomalous perceptions of reality, which contribute uniquely to suicidality [29]. Similarly, gender differences modulate OCD symptomatology and suicide risk, with depressive symptoms mediating suicide risk in both sexes but possibly varying in their expression and severity [30]. Moreover, immune factors like IL-17 A may interact differently due to these gender-specific neurobiological and psychosocial variables. Given these complexities, a personalized medicine approach is warranted. This could include immune biomarker profiling, such as IL-17 A, to identify those at greater risk or who might benefit from adjunctive immunomodulatory therapies. Potential solutions may involve integrating anti-inflammatory treatments alongside conventional psychiatric interventions, tailoring approaches based on demographic and clinical profiles to optimize outcomes. There was discrepancy between the logistic regression and GLMtree results. It likely reflects methodological differences between global and tree-based approaches rather than true contradictions. Logistic regression estimates an average effect across all participants under the assumption of linearity and additivity, whereas GLMtree is designed to identify subgroups in which the effect of a predictor (e.g., IL-17 A) may differ depending on other variables (e.g., diagnosis, sex, medication). Therefore, the GLMtree splits may reveal effect heterogeneity that is not captured by a single global coefficient. In small samples and particularly in small subgroups, these complex interactions can appear as directional inconsistencies and should be considered exploratory. Additionally, the tree model tends to display only the strongest associations at initial splits, meaning that weaker relationships may remain comparatively masked [31]. The GLMtree analyses were exploratory and intended to generate hypotheses about potential subgroups with different biomarker-symptom relationships rather than to provide definitive causal or prognostic models. Conclusion The study confirms that BMD patients exhibit a higher prevalence of suicidal thoughts and behaviors compared to those with SCZ, reflecting differences in mood instability and clinical features. Elevated serum IL-17A and CCL20 levels in both groups reinforce the probability role of neuroinflammation in these disorders, with IL-17A specifically maybe linked to suicidality in bipolar disorder. The probability and complex interactions of IL-17A with gender, ethnicity, treatment, and diagnosis underscore the need for personalized approaches integrating immune biomarker profiling and targeted immunomodulatory therapies to improve risk assessment and patient outcomes in psychiatric care. The primary contribution of this study is to provide preliminary evidence supporting a potential link between specific inflammatory markers and clinically important phenomena (OCD and suicidality) in severe psychiatric disorders. These findings may guide future mechanistic and longitudinal research rather than immediate changes in clinical practice. Limitations This study has several limitations. As a cross-sectional design, it restricts the ability to infer causality or understand temporal changes. The relatively small number of OCD subgroup, limits the statistical power and precision of our estimates. Consequently, the observed associations in this subgroup should be interpreted with caution, as they may be unstable and susceptible to both type I and type II errors. The consecutive sampling from a single psychiatric hospital limits the broader applicability of the findings, as the sample may not reflect the diversity of patients with SCZ or BMD seen elsewhere, including outpatient or community settings. Additionally, measuring cytokine levels solely during acute episodes does not account for their potential fluctuations over time or responses to treatment, thus limiting insight into the dynamic nature of immune changes in these disorders. Addressing these limitations would require longitudinal studies, and larger samples with repeated biomarker measurements across multiple centers and more varied populations to better clarify the complex relationships between immune factors and psychiatric symptoms. Acknowledgements The authors would like to gratefully acknowledge the research deputy of Mashhad University of Medical Sciences. Author contributions Conceptualization and supervision: Parisa Ghasemi Noghabi, Yasser Bagheri, Zanireh salimi, Najmeh Shahini; Methodology and data collection: Mostafa Eghbalian, Mojtaba Norouzi, Parisa Ghasemi Noghabi; Data analysis: Mostafa Eghbalian; Investigation and writing: All authors. Funding No funding was received to assist with the preparation of this manuscript. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Najmeh Shahini and Parisa Ghasemi Noghabi contributed equally to this work. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.